HOME > TOP STORIES
TOP STORIES
-
REGULATORY Pfizer, Bayer to Pull Plug on “G1” Products with High Generic Erosions
March 5, 2021
-
REGULATORY MHLW Announces New Drug Prices for 1st Off-Year Revision in April
March 5, 2021
-
ORGANIZATION Fast-Track Approval System, New Pricing Rules Needed for Therapeutic Apps: DTx Consortium
March 5, 2021
-
BUSINESS Nichi-Iko Chief Apologizes for GMP Violations, but Draws Clear Distinction from Kobayashi Kako Case
March 4, 2021
-
BUSINESS AbbVie Japan to Boost Immunology Reps as It Gears Up for Rinvoq/Skyrizi Label Expansions
March 3, 2021
-
REGULATORY Nichi-Iko Ordered to Suspend Biz over Sloppy Manufacturing
March 3, 2021
-
REGULATORY Woman Dies 3 Days after COVID-19 Vaccine Shot, but Link Indeterminable
March 3, 2021
-
BUSINESS Iwasaki to Bow Out as Chief of Takeda’s Japan Pharma Biz Unit
March 3, 2021
-
BUSINESS Kyowa Kirin Poised to Speed Up Growth with 5 Strategic Launches, Eyes Blockbuster Potential in Eczema Med
March 2, 2021
-
REGULATORY Nichi-Iko to Get Business Suspension Order on March 3
March 2, 2021
-
BUSINESS Takeda to Offload 4 Diabetes Meds in Japan to Teijin for 133 Billion Yen
March 1, 2021
-
REGULATORY Govt to Deliver 1st COVID-19 Vaccine Dose for 3.7 Million HCPs in April: Minister
March 1, 2021
-
REGULATORY Japan Research Group to Wrap Up Report on Clinical Trials for Cannabis-Derived Drugs by March-End
February 26, 2021
-
BUSINESS Meiji to Discontinue Sale of Kobayashi Kako Products after Biz Suspension
February 26, 2021
-
BUSINESS MSD’s 9-Valent HPV Vaccine Now Available in Japan
February 25, 2021
-
REGULATORY Japan to Start Elderly Vaccine Rollout from April 12: Minister
February 25, 2021
-
BUSINESS Takeda Launches Japan PI/II Trial of Novavax COVID-19 Vaccine
February 25, 2021
-
REGULATORY MHLW to Revise Dyslipidemia Drug Development Guideline for 1st Time in 30 Years
February 25, 2021
-
BUSINESS Japan Pharma Market Shrinks 2.4% on COVID-19, Price Cuts: IQVIA
February 24, 2021
-
REGULATORY LDP to Set Up Project Team to Strengthen Pharma Sector, Eyes Proposal in May
February 22, 2021
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
